Atheronova Inc (AHRO) 0.0235 $AHRO AtheroNova and its

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Atheronova Inc (AHRO) 0.0235 $AHRO

AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection
PR Newswire - Tue Mar 03, 7:45AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and its subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court, Central District of California, Santa Ana division (the "Bankruptcy Court" on March 2, 2015. The Company's Chapter 11 cases are expected to be jointly administered.

MicroCap Outlook for Thursday February 19, 2015
ACCESSWIRE - Thu Feb 19, 8:20AM CST
CORAL GABLES, FL / ACCESSWIRE / February 19, 2015 / Big returns often come in small packages so they say. Since the bull market started in March 2009, the Russell 2000 index is up 215% compared to a 180% gain in the S&P 500. In addition to this, statistics from Vanguard show that between 1927 and 2012, small-cap stocks produced average annual returns of 12.9% vs. a 9.9% gain for their larger counterparts. Small and micro-cap stocks have gotten an unfair reputation as being too risky or volatile for many investors. The truth is, however, that many who write off these asset classes are missing out on solid earnings potential from some of fastest growing and innovative companies in the market.

AtheroNova awarded Notice of Issuance of third US patent
M2 - Mon Feb 16, 5:49AM CST
AtheroNova (Other OTC:AHRO) reported on Friday that it has received a Notice of Issuance of Patent No. 8952067 titled 'Subcutaneous Fat Reduction' from the US Patent and Trade Office, with an expiration date of 20 June 2032.

AtheroNova Receives Notice of Debt Acceleration
PR Newswire - Fri Feb 13, 2:23PM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it filed a Current Report on Form 8-K disclosing that on February 12, 2015 it received a notice of acceleration from Europa International, Inc., the holder of a 2.5% Senior Secured Convertible Note ("2.5% Note" issued by the Company in the principal amount of $427,500. The 2.5% Note was due and payable on November 12, 2014 and the holder was entitled to accelerate outstanding amounts under the 2.5% Note on November 26, 2014. While the Company attempted to negotiate an extension of the maturity date of the 2.5% Note, those negotiations were ultimately unsuccessful. The acceleration of the indebtedness under the 2.5% Note entitles the holder to receive 120% of the outstanding principal plus accrued and unpaid interest and other costs and expenses arising thereunder. The 2.5% Note also began to accrue interest at 12% per annum from November 26, 2014.

AtheroNova Receives Notice of Issuance of Its 3rd US Patent
PR Newswire - Fri Feb 13, 7:10AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.

AtheroNova concludes USD3m in public offering
M2 - Mon Nov 03, 3:39AM CST
Biotech company AtheroNova (Other OTC:AHRO) disclosed on Friday the completion of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.

AtheroNova Prices Public Offering of Common Stock and Warrants
PR Newswire - Tue Oct 28, 4:58PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant. The warrants will have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and will expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are expected to be $3,050,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. The offering is expected to close on or about October 31, 2014, subject to customary closing conditions. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

SRM Entertainment Expands Horizon with Strategic Moves.

Updated Category News Views 238

SRM Entertainment's Strategic Growth Plans SRM Entertainment, Inc. (Nasdaq: SRM) is taking bold steps to enhance its market position and create long-term value for its shareholders. Despite receiving numerous inquiries from investors regarding potential capital raises, the company has confirmed no immediate plans to seek additional funding. This strategic decision aligns...

Continue Reading
SBA Communications Unveils Tax Reporting Details for 2024

Updated Category News Views 149

SBA Communications Corporation Announces 2024 Tax Reporting Insights SBA Communications Corporation (Nasdaq: SBAC) has shared important tax reporting information concerning its distributions for 2024. As stockholders prepare for their tax obligations, the company encourages them to seek advice from their personal tax advisors to ensure they understand their specific tax...

Continue Reading
electroCore Achieves Significant Milestone with New Patents

Updated Category News Views 157

electroCore Enhances Innovation Through New Patents electroCore, Inc. (NASDAQ: ECOR), a leading figure in the bioelectronic medicine and wellness space, has recently made headlines by receiving notifications for five new patents issued by the United States Patent and Trademark Office (USPTO). This expansion of its intellectual property portfolio not only underscores...

Continue Reading
Empowering Grassroots: A Great Idea’s New Microgrant Initiative

Updated Category News Views 252

Introducing the A Great Idealist Microgrant Program A Great Idea (AGI) has recently unveiled its A Great Idealist Microgrants program, designed to provide crucial financial support to grassroots organizers, community advocates, and innovative leaders across the nation. This initiative echoes AGI's commitment to uplift and empower those at the forefront of social change....

Continue Reading
Elevat and HydraForce Team Up for Game-Changing Solutions

Updated Category News Views 249

Dynamic Partnership Set to Transform OEM Offerings What’s brewing in the world of industrial machine intelligence? It’s more than a merger—it’s a strategic collaboration that’s about to shake things up. Elevat, that Seattle-based powerhouse known for its cutting-edge solutions, has joined forces with HydraForce, backed by Bosch, to roll out some impressive...

Continue Reading